Lv0
0 积分 2022-01-12 加入
[Expert consensus on diagnosis and treatment of malignant pleural effusion caused by lung cancer]
8天前
已完结
[Chinese expert consensus on treatment of malignant pleural effusion (2023 Edition)]
8天前
已完结
MO06.03 Bevacizumab and erlotinib or bevacizumab, cisplatin and pemetrexed in patients with metastatic non-small cell lung cancer: EGFR mutation based treatment allocation and repeat biopsy at progression in the SAKK19/09 (BIOPRO) trial
15天前
已关闭
Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib
15天前
已完结
Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non–Small-Cell Lung Cancer Patients With EGFR Mutation
15天前
已完结
Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab With and Without Atezolizumab in Stage IV Nonsquamous Non–Small-Cell Lung Cancer Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked
15天前
已完结
Identifying Early-Phase Clinical Trial Participants at Risk for Experiencing Worse Clinical Outcomes
2个月前
已完结
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
4个月前
已完结
恶性胸腔积液诊断与治疗专家共识
4个月前
已完结
First-Line Nivolumab Plus Ipilimumab With Chemotherapy for Metastatic NSCLC: The Updated Outcomes From CheckMate 9LA
4个月前
已关闭
皖公网安备34019202002308
